| Document |
Document Title |
|
WO/2024/040256A2 |
Provided is a pharmaceutical combination for preventing or treating a neurodegenerative disease. The pharmaceutical combination includes a first agent being an insulin sensitizer and a second agent being a lipid metabolism modulator. Als...
|
|
WO/2024/036787A1 |
Disclosed is use of brain-refreshing marker genes nr1d4a and nr1d4b in screening a brain-refreshing medicament, relating to the technical field of medicament screening. Particularly, disclosed is a method for screening a brain-refreshing...
|
|
WO/2023/250325A9 |
The present disclosure provides methods and compositions for reducing the level of an RNA transcript produced from a mutant Huntingtin (mHtt) allele in a neuron in an individual with Huntington's disease. The present disclosure provides ...
|
|
WO/2024/037536A1 |
The present invention provides a sustained-release formulation containing varenicline and a preparation method therefor, and relates to the field of pharmaceutical formulations. The sustained-release formulation comprises 20-60 parts of ...
|
|
WO/2024/039886A1 |
Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with ce...
|
|
WO/2024/039599A1 |
The subject matter disclosed generally relates to phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described technology allows slow/sustained/controlled delivery of the parent phenethyl...
|
|
WO/2024/039229A1 |
The present invention relates to: novel lactic acid bacteria, Lactococcus lactis P32 (KCCM13222P) and Bifidobacterium bifidum P45 (KCCM13223P), or a mixture thereof; and uses thereof. Strains and a mixture thereof, according to the prese...
|
|
WO/2024/040182A1 |
Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine or a pharmaceutically acceptable thereof to treat cancers and precancer lesions, including cancers and precancer lesions associated with papilloma virus ...
|
|
WO/2024/040095A2 |
The invention provides pharmaceutical compositions comprising molecules capable of disassembling tau amyloid fibrils or alpha-synuclein amyloid fibrils, as well as methods for making compositions comprising these molecules. Embodiments o...
|
|
WO/2024/038160A1 |
The application concerns a novel hominid-specific pathway to modulate neuronal excitability. In a first aspect, the application relates to a modulator of the interaction between a LRRC37B protein and the NAV1.6 voltage-gated sodium chann...
|
|
WO/2024/039203A1 |
The present invention relates to a magnetic torquer (m-Torquer) conjugant-based drug. Specifically, according to the present invention, an m-Torquer conjugant having (a) magnetic nanoparticles that generate torque upon application of a c...
|
|
WO/2024/038289A1 |
This invention relates to pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine. In particular, though not exclusively, the invention relates to compositions/formulations and uses of the same as a medicament.
|
|
WO/2024/037389A1 |
A biomarker miR-32533 for cognitive impairment-related diseases and use thereof. The miR-32533 comprises a nucleotide sequence represented by SEQ ID NO. 1, can be used as a biomarker for detecting cognitive disorder impairment-diseases, ...
|
|
WO/2024/039256A1 |
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of "weari...
|
|
WO/2024/040123A1 |
The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the...
|
|
WO/2023/143609A9 |
The present application provides methods of altering ApoE4 in a cell comprising a nucleic acid encoding ApoE4 by introduction of components of a nucleic acid editing system, thereby producing an ApoE4 with altered function. Also provided...
|
|
WO/2024/038010A1 |
The present invention relates to a kit of nutrient blend compositions for young individuals, in particular children aged between 0 and 66 months, each one of the compositions having age-specific ingredients. The kit of nutrient blend com...
|
|
WO/2024/032755A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/035946A1 |
Among other things, the present disclosure provides various oligonucleotide technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing such oligonucleotide compositions. In some embodiments...
|
|
WO/2024/036225A1 |
The present invention provide methods of treating or preventing a condition related to acute or chronic excessive glutamate exposure using epicatechin or pharmaceutical compositions thereof. Methods of decreasing reactive oxygen species ...
|
|
WO/2024/033896A1 |
The present disclosure relates to small interfering RNAs, which target IDO1 mRNA in a cell, leading to reduced expression of IDO1 protein. Reduction of IDO1 protein expression is beneficial for the treatment of certain medical disorders,...
|
|
WO/2024/035015A1 |
The present invention relates to a composition for prevention, alleviation, or treatment of neurodegenerative diseases, comprising fexofenadine. Fexofenadine, a compound already commercialized for pharmacological purposes, has proven to ...
|
|
WO/2024/033946A1 |
The present disclosure relates to compositions and methods for preventing or treating a cognitive deficit in a subject. The compositions comprise a barley extract as an active ingredient.
|
|
WO/2024/036112A1 |
Described herein are amide prodrugs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating a CNS disease or disorder.
|
|
WO/2024/031131A1 |
The present disclosure relates generally to novel compositions and methods for delivery of truncated midkine proteins in which the amino acid sequence encoded by exon 4 of human midkine is absent or partially absent and/or polynucleotide...
|
|
WO/2024/036223A1 |
The present invention provide methods of inhibiting ATP hydrolysis using epicatechin or pharmaceutical compositions thereof. Methods of preventing Electron Transport Chain (ETC) complex V dissociation into monomers and decreasing ATP hyd...
|
|
WO/2024/032750A1 |
Provided are an antibody specifically binding to CGRP or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a v...
|
|
WO/2024/036257A1 |
Provided herein are methods for treating drug addiction in a subject, the method comprising activating neurokinin B (NKB)-expressing neurons of the subject. Also provided herein are compositions useful for the treatment of drug addiction...
|
|
WO/2024/033460A1 |
The present invention relates to the use of co-processed excipients in continuous manufacturing of solid dosage forms.
|
|
WO/2024/035626A1 |
Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to ...
|
|
WO/2024/031163A1 |
The present invention describes opioid peptides that can be used to prepare antinociceptive medicines. Specifically, the present invention comprises three peptides with surprising antinociceptive efficacy and no detectable adverse effect...
|
|
WO/2024/033845A1 |
The invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a hydrate thereof:, wherein X, Y, R1, R2, R3, R4, R5, and R6 are as defined in the specification, for treatment of ...
|
|
WO/2024/033910A1 |
Provided herein are freeze-dried psychedelic compositions including a mixture of fruit and/or vegetable puree; an edible oil; and a psychedelic; wherein the freeze-dried psychedelic composition is a single dose composition that melts in ...
|
|
WO/2024/032821A1 |
Provided is a new and highly toxic amyloid oligomer Aβo*3F. The Aβo*3F is specifically bound by a 3F antibody, is the most important toxic ingredient in a mixture of Aβ oligomers, and has a strong pathogenic effect. Further provided i...
|
|
WO/2024/032822A1 |
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of a W20 antibody. Compared with the W20 antibody, the improved f...
|
|
WO/2024/036005A1 |
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
|
|
WO/2024/034644A1 |
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/032501A1 |
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, a...
|
|
WO/2024/033479A1 |
The application relates to compounds of formula (B1A), (B1B), (B1C) or a salt, a solvate, a hydrate, a polymorph, a tautomer, a racemate or a stereoisomer thereof, to pharmaceutical compositions comprising such a compound, and to the com...
|
|
WO/2024/032530A1 |
Provided are an aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, a preparation method and a use thereof. Specifically, provided are a compound of formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutic...
|
|
WO/2024/035194A1 |
The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative ...
|
|
WO/2024/036226A1 |
Provided herein is a method for treating autism or autism spectrum disorders. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating autis...
|
|
WO/2024/035268A2 |
Pharmaceutical compositions and methods for treating tauopathies are provided.
|
|
WO/2024/033539A1 |
The present disclosure provides cannabinoid drug substances, pharmaceutical compositions and methods of treating neurological or neurodegenerative disorders in a human patient.
|
|
WO/2024/033895A2 |
The present disclosure relates to antisense oligonucleotides, which target IDO1 mRNA in a cell, leading to reduced expression of IDO1 protein. Reduction of IDO1 protein expression is beneficial for the treatment of certain medical disord...
|
|
WO/2024/033459A1 |
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.
|
|
WO/2024/031889A1 |
The present invention relates to the field of biotechnology, and specifically, to use of a gene delivery system in delivering a gene to microglial cells, or in preparing a reagent for delivering a gene to microglial cells. The gene deliv...
|
|
WO/2024/032390A1 |
Provided are a macrocyclic triazole compound represented by formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt, or a ...
|
|
WO/2024/032507A1 |
Provided are a metal-phospholipid complex, a metal-phospholipid complex particle, a drug-lipid particle, a method for preparing same, and use thereof, which relate to the field of biotechnology. The metal-phospholipid complex is formed b...
|
